Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 25 entries
View as:

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT02588833 Org: User:
Start: 12/01/15 End: 08/26/19 Due: 08/26/20

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase: N/A Priority: Normal
NCT ID: NCT04901936 Org: User:
Start: 02/04/21 End: 12/31/28 Due: 12/31/29

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT02503332 Org: User:
Start: 09/24/15 End: 01/17/18 Due: 01/17/19

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04402060 Org: User:
Start: 05/28/20 End: 02/13/21 Due: 02/13/22

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT06161584 Org: User:
Start: 09/28/23 End: 06/30/28 Due: 06/30/29

C3G/Primary IC-MPGN EAP

Phase: N/A Priority: Normal
NCT ID: NCT04729062 Org: User:
Start: - End: - Due: -

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT03525613 Org: User:
Start: 08/31/18 End: 06/28/22 Due: 06/28/23

Geographic Atrophy Long-Terms Outcomes Study

Phase: N/A Priority: Normal
NCT ID: NCT06499571 Org: User:
Start: 09/01/22 End: 07/31/23 Due: 07/31/24

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Phase: N/A Priority: Normal
NCT ID: NCT05809531 Org: User:
Start: 05/29/23 End: 07/31/27 Due: 07/31/28

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase: N/A Priority: Normal
NCT ID: NCT04579666 Org: User:
Start: 09/30/20 End: 07/13/23 Due: 07/13/24

Pegcetacoplan Long Term Safety and Efficacy Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT03531255 Org: User:
Start: 08/27/18 End: 06/30/25 Due: 06/30/26

Pegcetacoplan (APL-2) in Neovascular AMD

Phase: N/A Priority: Normal
NCT ID: NCT03465709 Org: User:
Start: 02/14/18 End: 04/05/19 Due: 04/05/20

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

Phase: N/A Priority: Normal
NCT ID: NCT02461771 Org: User:
Start: 01/28/15 End: 03/08/16 Due: 03/08/17

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT07020832 Org: User:
Start: 09/30/25 End: 08/31/28 Due: 08/31/29

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Phase: N/A Priority: Normal
NCT ID: NCT05067127 Org: User:
Start: 11/12/21 End: 01/14/25 Due: 01/14/26

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Phase: N/A Priority: Normal
NCT ID: NCT03453619 Org: User:
Start: 02/26/18 End: 08/26/23 Due: 08/26/24

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT03777332 Org: User:
Start: 11/05/18 End: 04/01/21 Due: 04/01/22

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

Phase: N/A Priority: Normal
NCT ID: NCT04085601 Org: User:
Start: 08/27/19 End: 06/23/21 Due: 06/23/22

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

Phase: N/A Priority: Normal
NCT ID: NCT02264639 Org: User:
Start: 02/23/15 End: 10/22/18 Due: 10/22/19

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase: N/A Priority: Normal
NCT ID: NCT03500549 Org: User:
Start: 06/14/18 End: 08/13/20 Due: 08/13/21

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT03525600 Org: User:
Start: 08/31/18 End: 06/20/22 Due: 06/20/23

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

Phase: N/A Priority: Normal
NCT ID: NCT04770545 Org: User:
Start: 03/04/21 End: 09/30/26 Due: 09/30/27

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Phase: N/A Priority: Normal
NCT ID: NCT04572854 Org: User:
Start: 09/07/21 End: 01/31/26 Due: 01/31/27

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Phase: N/A Priority: Normal
NCT ID: NCT03226678 Org: User:
Start: 08/31/17 End: 09/12/22 Due: 09/12/23

A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

Phase: N/A Priority: Normal
NCT ID: NCT03593200 Org: User:
Start: 08/16/18 End: 10/22/19 Due: 10/22/20